Exact Sciences (NASDAQ: EXAS) reported Q1 EPS of ($0.54), $0.21 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $707 million versus the consensus estimate of $688.78 million.

GUIDANCE:

Exact Sciences sees FY2025 revenue of $3.07-3.12 billion, versus the consensus of $3.9 billion.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.